AstraZeneca presents a bull case with consistent 8-10% annual revenue growth at $60B+ scale, expanding EBITDA margins toward 33%, and declining leverage (1.23x net debt/EBITDA). Near-unanimous analyst consensus (8 Buy/1 Sell) with $224 average price target implies 26% upside, supported by dominant franchises in oncology (Tagrisso, Enhertu) and cardio-renal (Farxiga). Key risks include patent cliffs (Tagrisso expiring ~2028), lone Deutsche Bank Sell rating, and below-1 current ratio indicating potential near-term liquidity pressure.